Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ultragenyx Pharmaceutical (RARE) Finished Goods: 2017-2025

Historic Finished Goods for Ultragenyx Pharmaceutical (RARE) over the last 8 years, with Sep 2025 value amounting to $23.0 million.

  • Ultragenyx Pharmaceutical's Finished Goods fell 0.18% to $23.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $23.0 million, marking a year-over-year decrease of 0.18%. This contributed to the annual value of $23.0 million for FY2024, which is 52.48% up from last year.
  • Latest data reveals that Ultragenyx Pharmaceutical reported Finished Goods of $23.0 million as of Q3 2025, which was down 13.95% from $26.7 million recorded in Q2 2025.
  • Over the past 5 years, Ultragenyx Pharmaceutical's Finished Goods peaked at $26.7 million during Q2 2025, and registered a low of $4.9 million during Q2 2022.
  • Moreover, its 3-year median value for Finished Goods was $15.1 million (2023), whereas its average is $17.8 million.
  • Per our database at Business Quant, Ultragenyx Pharmaceutical's Finished Goods decreased by 13.08% in 2022 and then soared by 107.99% in 2023.
  • Over the past 5 years, Ultragenyx Pharmaceutical's Finished Goods (Quarterly) stood at $5.7 million in 2021, then spiked by 62.04% to $9.3 million in 2022, then soared by 62.82% to $15.1 million in 2023, then soared by 52.48% to $23.0 million in 2024, then decreased by 0.18% to $23.0 million in 2025.
  • Its Finished Goods stands at $23.0 million for Q3 2025, versus $26.7 million for Q2 2025 and $23.1 million for Q1 2025.